NetraMark’s AI Enhances Psychiatric Drug Trials
Company Announcements

NetraMark’s AI Enhances Psychiatric Drug Trials

Netramark Holdings Inc (TSE:AIAI) has released an update.

NetraMark Holdings Inc. has revealed its AI software, NetraAI, can significantly improve the success rates of clinical trials for psychiatric medications by predicting efficacy and placebo responses with high accuracy. Presented at the ISCTM Annual Meeting, the technology has shown promise in identifying key variables within small patient data sets that could streamline future clinical trials and enhance the development of mental health therapies. The AI’s ability to generate insights from smaller samples could be crucial in addressing the mental health crisis more efficiently.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNetraMark Appoints Oncology Expert P.J. Haley to Board
TipRanks Canadian Auto-Generated NewsdeskNetraMark Unveils New Suite to Revolutionize Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskNetraMark’s Q3 Success with AI Clinical Trial Analytics
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App